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Abstract
BACKGROUND: The aim of this study was lymphatic mapping
to identify SLN in cervical cancer (CaCerv) with radioactive colloids,
intraoperative detection with patent blue dye (PBD) and gamma
probe (GP) and biopsy and comparison of two protocols.
MATERIAL AND METHODS: In 54 patients with CaCerv before
hysterectomy and lymph nodes dissection (LND) we performed
preoperative lymphoscintigraphy utilizing 99mTc-colloid (Nano-
coll, SentiScint or Nanocis), activity 40 MBq,  on the operation
day (30 women) or the day before operation (24 women). Gy-
naecologists injected 4 peritumoural injections of colloid into
the cervix around the tumour. Scintigraphy followed 2550 mi-
nutes (one-day protocol) or 1219 hours (two-day protocol) af-
ter injection. Gynaecologists also injected 4 peritumoural injec-
tions of PBD into the cervix around the tumour.  All women un-
derwent SLN biopsy and LND (in average 35 lymph nodes were
taken) and hysterectomy. SLNs (active and/or blue lymph
nodes) were examined by a pathologist [histopathology and
immunohistochemistry (IH) with detection of cytokeratine].
No SLN was examined without IH.
RESULTS: The gynaecologists withdrew 123 SLNs (on aver-
age 2.27/1 patient) and in total 1898 lymph nodes (on average
35/1 patient). In 1 woman the tumour was inoperable. Two-day
protocol, which involved scintigraphy, PBD and GP detected
SLNs on both sides (45 SLNs) in 17 women (70.8%), SLNs
on the one side (6 SLNs) in 3 patients (12.5%) and no SLNs were
found in 4 women (16.7%). One-day protocol detected SLNs
on both sides in 23 patients (74.1%)  63 SLNs, in 7 women
on one side (25.9%)  9 SLNs. Metastases in SLNs (with
or without metastases in other LN) were found in 21 patients
(38.9%)  in 1 woman of stage FIGO IB1, in 1 woman of stage
FIGO IB2, in 1 patient of stage FIGO IIIA and in all 18 patients
of stage FIGO IIIB. False negative SLN detection was 0%.
CONCLUSIONS: In SLN detection in patients with CaCerv,
all 3 methods  scintigraphy, PBD and GP  should be used,
and the success rate of SLN detection increases, although scin-
tigraphy has lower significance than in SLN detection in malig-
nant melanoma and breast cancer. One-day protocol had
a better detection rate of SLN than two-day protocol. The meth-
od is promising but its results are not as unequivocal and opti-
mistic as in breast cancer and malignant melanoma, and it
is still experimental. Additional experience is necessary.
Key words: cervical cancer, sentinel lymph node,
lymphoscintigraphy, patent blue dye, surgical gamma probe
Introduction
In many tumours, lymph node staging is performed using
various nuclear medicine procedures, especially sentinel lymph
node (SLN) biopsy. SLN biopsy has an established role in ma-
lignant melanoma and breast cancer [1, 2]. A group of patients
who might benefit from a SLN biopsy are those with cancer
of the uterine cervix and other gynaecological malignancies.
In gynaecologic malignancies, regional lymph node status is
a major prognostic factor and a decision criterion for adjuvant
therapy [3]. Current FIGO staging is unreliable. The reliability
of staging can be improved by laparoscopic staging and new
imaging techniques such as PET. These techniques still have
to be refined [4].
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Material and methods
Gynaecologists injected 4 peritumoural injections of radiocol-
loid, activity 40 MBq (in volume 4 × 0.5 ml) into the cervix, around
the tumour. Scintigraphy followed 2550 minutes (one-day protocol)
or 1219 hours (two-day protocol) after injection. 54 patients (age
range 2576 yrs; average age 48.3 yrs) with CaCerv were studied
and operated on.
Staging of CaCerv in our patients was: FIGO IA1 in 1 patient,
IA2 in 2 patients, IB1 in 30 patients, IB2 in 2 patients, IIIA
in 1 patient, IIIB in 18 patients.
Before hysterectomy and lymph nodes dissection (LND)
we carried out preoperative lymphoscintigraphy (Figure 1, Figure 2)
with the following 99mTc colloids: 1. Two-day protocol: in one pa-
tient Nanocis  99mTc-colloid rhenium sulphide  nanocolloid
(Cis bio International, Gif-sur-Yvette Cedex, France), in 17 patients
Nanocoll  99mTc-nanocolloid of human serum albumin (Nycomed
Amersham Sorin, Saluggia, Italy), in 6 patients SentiScint  99mTc-hu-
man serum albumin colloid  (FJC National Research Institute for
Radiobiology and Radiohygiene, Budapest, Hungary); 2. one-day
protocol: in 29 patients SentiScint and in 1 patient Nanocoll. Lym-
phoscintigraphy was carried out on the operation day (30 wo-
men) or the day before operation (24 women) in the anterior projec-
tion on a planar gamma-camera MB 9200 (Gamma, Budapest,
Hungary) with a high-resolution collimator focusing on the area
of interest. Acquisition time was 10 minutes. If the sentinel lymph
node was displayed, to facilitate the surgical resection a refer-
ence mark was placed on the skin, corresponding to the position
of the SLN visualised by lymphoscintigraphy with the help of the
57Co mark (before this the occurrence spot was marked with self-
adhesive label on the computer monitor  for better orientation
upon marking). The skin surface, under which the lymph node
was located, was marked by felt-tip pen cross first and subse-
quently with dye.
Surgery followed 1.54 hours (one-day protocol) or 1420 hours
(two-day protocol) after radiocolloid injections. Gynaecologists
Figure 1. Scintigraphic detection of SLN in cervical cancer  anterior projection. A. Image with the lead plate covering injection sites; B. Without the
lead plate.
A B
Figure 2. Scintigraphic detection of SLN in cervical cancer  anterior
projection.
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injected 4 peritumoural injections of 4 ml PBD (Patent Blue V 
or Blue PatentØ V, Laboratoire Guebert, Aulnay-sous-Bois, France)
into the cervix around the tumour and they intra-operatively de-
tected blue-stained SLNs (or lymph vessels) and radioactive SLN
by means of surgical gamma probe DI SURPO (Delong Instru-
ments, Brno, Czech Republic). All women underwent LND and
radical surgery  hysterectomy according Wertheim-Meigs with
radicalism PIVER II, III. Radioactive and/or blue-stained lymph
nodes (SLN) were examined by the pathologist histopathology
 formol fixation, parafin embedding, serial sectioning, hemato-
xylin and eosin, PAS staining and immunostaining with a mono-
clonal mouse anti-human cytokeratin/Clone AE1 (AE3 antibody
DAKO). No SLNs were examined without immunohistochemistry.
Results
The gynaecologists withdrew 123 SLNs (in average 2.27/1
patient), in total 1898 lymph nodes (on average 35 lymph nodes
were taken in each patient). In 1 woman the tumour was inopera-
ble. Two-day protocol: scintigraphy, PBD and GP detected SLN
on both sides (45 SLN) in 17 women (70.8%), SLN on the one
side (6 SLN) in 3 patients (12.5%) and SLN were not found
in 4 women (16.7%). Detection rate of SLN was 83.7%. These 4 wom-
en without SLN detection had CaCerv of these stages: 2 × FIGO
1B1 in 2 patients, FIGO IB2 in 1 patient and FIGO IIIB in 1 patient.
In 3 patients with unsuccessful SLN detection we used Nanocoll and
in one woman SentiScint.  One-day protocol results were: SLN was
detected on both sides in 23 patients (74.1%)  63 SLNs, and
in 7 women on one side (25.9%)  9 SLNs. Detection rate of SLN
was 100%. Tables 1 and 2 show detection rates of SLNs.
Metastases in SLNs (with or without metastases in other LN) were
found in 21 patients (in 38.9%)  in 1 woman of stage  FIGO IB1,
in 1 woman of stage FIGO IB2, in 1 patient of stage FIGO IIIA and in all
18 patients of stage FIGO IIIB (Figure 3  IH detection of cytokeratine
in SLN metastases). False negative rate of SLN detection was 0.
Discussion
In the Czech Republic, cervical cancer is the third most
common gynaecological malignant tumour with incidence
of 20 cases per 100 thousand women, which is the highest
in Europe.
The main factors which have influence on the prognosis are:
disease stage, type, size and differentiation of tumour. The most
important prognostic factor is the state of the lymph nodes. The treat-
ment of choice in clinically node-negative early stage cervical cancer
(up to stage IIa) is radical hysterectomy and pelvic lymph node dis-
section [5], in higher stages (the frontier is affliction of parametrium)
the primary treatment is radiotherapy. Radical surgery according
Wertheim-Meigs with radicalism PIVER II, III consists of withdrawal
of the uterus, adnexa, parametria, proximal part of vagina and pelvic
lymph nodes. Complications resulted from extensive radicalism
of surgery are lymphocyst formation, lymph drainage blockade with
lymphoedema formation of lower extremities. Affliction of the lym-
phatic system is in the stage FIGO I up to 15%, in the stage FIGO II
2530 %. There is not suitable pre-surgery examination procedure
of detection of impacted lymph nodes. SLN biopsy can be feasible
in cervical cancer and may result in custom-designed treatment strat-
egies with a reduction in morbidity. The most important benefits
of the SLN procedure for the patients with cervical cancer are avoida-
nce of over treatment and prevention of morbidity [6].
Table 1. Sentinel lymph node detection  one-day protocol
SLN detection Scintigraphy Gamma probe Patent blue dye Perioperative-combination
Number of patients 30 29 29 30
Successful detection 23 28 23 30
Percentage of SLN detection 76.7 96.6 79.3 100
SLN  sentinel lymph node
Table 2. Sentinel lymph node detection  two-day protocol
SLN detection Scintigraphy Gamma probe Patent blue dye Perioperative-combination
Number of patients 24 23 22 24
Successful detection 22 17 18 20
Percentage of SLN detection 91.7 73.9 81.8 83.3
SLN  sentinel lymph node
Figure 3. Immunohistochemistry (IH) detection of cytokeratine in SLN me-
tastases of cervical cancer.
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Detection rate of SLN can be negatively influenced by the FIGO
stage and primary cervical tumour size [7]. We had small amount
of patients and we could not confirm this connection. We had
a lower scintigraphic SLN detection than gamma probe detection
by Wydra et al. [8]. The injected tracer amount is another factor that
can influence SLN visualization [9]. Particle size of radiocolloid can be
also significant. We had a small amount of patients in Nanocoll and
SentiScint subgroups and it is not possible to draw conclusions about
influence of particle colloid size. Namkoong et al [10] recommend
99mTc-antimony sulphide colloids with the size of particles ranging 1 to
15 nm. We think that this size is too small with a high possibility for
second echelon lymph node visualization. The sentinel lymph node
concept is valid in patients with cervical cancer [11]. However, sensi-
tivity and negative predictive value have to be improved before the
concept can be integrated into clinical practice [4], and large and multi-
institutional trials are required in order to define the implementation
of SLN biopsy in clinical practice with the objective of achieving safer
and more conservative surgery [12].  However, some authors have
proven high and unacceptable false negative rates of SLN in cervi-
cal cancer. This high false-negative rate associated with sentinel
lymph node biopsy raises questions regarding the validity of the
sentinel lymph node concept in cervical carcinoma [13]. In recent
studies, the usefulness of SLN biopsy in the early stages of cervical
cancer with highly negative predictive value was proven [14, 15].
Conclusions
In SLN detection in patients with CaCerv, all 3 methods  scin-
tigraphy, PBD and GP - should be used and the success rate of SLN
detection increases, although scintigraphy has a lower significance
than in SLN detection in malignant melanoma and breast cancer.
One-day protocol has better detection rate of SLN than two-day pro-
tocol. The method is promising but its results are not as unequivocal
and optimistic as in breast cancer and malignant melanoma, and
it is still experimental. Additional experience is necessary (learning
curve). Sentinel lymph node concept is valid in patients with cervical
cancer. However, sensitivity and negative predictive values have to be
improved before the concept can be integrated into clinical practice.
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